Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510)

B. D. Cheson, N. L. Bartlett, J. M. Vose, A. Lopez-Hernandez, A. L. Seiz, A. T. Keating, S. Shamsili, K. P. Papadopoulos, Kyriakos P. Papadopoulos

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)4365
Number of pages1
Issue number17
StatePublished - Sep 1 2012
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this